









Markets
/
Stocks
/
nasdaq-tcrx
/

TScan Therapeutics Inc

TCRX

1.030USD

+0.120+13.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

58.45MMarket Cap

LossP/E TTM



TScan Therapeutics Inc

1.030

+0.120+13.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of TScan Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

TScan Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 109 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TScan Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

109 / 392

Overall Ranking

239 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

TScan Therapeutics Inc Highlights

StrengthsRisks

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.82M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.82M.

Overvalued

The company’s latest PE is -0.92, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 39.04M shares, decreasing 22.03% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 829.92K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.36.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.000

Target Price

+628.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of TScan Therapeutics Inc is 6.46, ranking 251 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.51M, representing a year-over-year increase of 139.37%, while its net profit experienced a year-over-year increase of 19.48%.

Score

Industry at a Glance

Previous score

6.46

Change



Financials

8.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.55

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

TScan Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of TScan Therapeutics Inc is 8.78, ranking 21 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.92, which is -40.75% below the recent high of -0.54 and -1286.17% above the recent low of -12.74.

Score

Industry at a Glance

Previous score

8.78

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of TScan Therapeutics Inc is 7.71, ranking 271 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 12.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.71

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.000

Target Price

+628.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

TScan Therapeutics Inc

TCRX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of TScan Therapeutics Inc is 5.94, ranking 286 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.23 and the support level at 0.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.36

Change

0.58

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.034

Sell

RSI(14)

46.243

Neutral

STOCH(KDJ)(9,3,3)

26.093

Buy

ATR(14)

0.073

High Vlolatility

CCI(14)

-82.555

Neutral

Williams %R

56.452

Sell

TRIX(12,20)

-0.277

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.984

Buy

MA10

1.029

Buy

MA20

1.094

Sell

MA50

1.051

Sell

MA100

1.395

Sell

MA200

1.519

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of TScan Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.40%, representing a quarter-over-quarter decrease of 7.19%. The largest institutional shareholder is The Vanguard, holding a total of 2.48M shares, representing 4.72% of shares outstanding, with 4.73% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

7.86M

BVF Partners L.P.

5.23M

K2 HealthVentures LLC

3.60M

+414.67%

Simplify Asset Management Inc

2.84M

-9.47%

Baker Bros. Advisors LP

2.78M

The Vanguard Group, Inc.

Star Investors

2.32M

+7.84%

abrdn Inc.

1.35M

+51.98%

BlackRock Financial Management, Inc.

1.25M

-4.90%

Bessemer Venture Partners

1.25M

Alphabet, Inc.

1.08M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TScan Therapeutics Inc is 1.72, ranking 288 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. TScan Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.